About

About AmbioPharm, Inc. AmbioPharm is a global leader in peptide manufacturing, specializing in the development and production of peptide-based Active Pharmaceutical Ingredients (APIs). Founded in 2005 and headquartered in North Augusta, South Carolina, USA, we are a patient-focused Contract Development and Manufacturing Organization (CDMO) with a reputation for technical excellence, innovation, and cost-effective solutions. Our state-of-the-art facilities in South Carolina, USA, and Shanghai, China, manufacture New Chemical Entities (NCEs) and peptide APIs under cGMP compliance, supporting pharmaceutical and biotech clients worldwide. AmbioPharm provides comprehensive peptide manufacturing solutions that support our clients from early-stage development through full-scale commercial production. Our expertise covers solid-phase, solution-phase, and hybrid synthesis, as well as organic conjugations to proteins, toxoids, antifungals, KLH (Keyhole Limpet Hemocyanin), and PEG (Polyethylene Glycol). We offer end-to-end peptide development services, including scale-up, validation, and process qualification leading up to New Drug Application (NDA) submissions with the U.S. Food and Drug Administration (FDA). With our advanced manufacturing facilities, robust quality systems, and cost-effective approach, AmbioPharm is the trusted partner for pharmaceutical and biotech companies seeking high-quality peptide APIs for both clinical and commercial applications. AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.